Voyager Therapeutics, Inc

(NASDAQ:VYGR)

Latest On Voyager Therapeutics, Inc (VYGR):

Date/Time Type Description Signal Details
2023-05-09 19:46 ESTNewsVoyager Therapeutics GAAP EPS of $2.94 beats by $1.90, revenue of $150.48M beats by $97.98MN/A
2023-05-09 19:45 ESTNewsVoyager Therapeutics, Inc. (VYGR) Q1 2023 Earnings Call TranscriptN/A
2023-05-08 16:52 ESTNewsVoyager Therapeutics Q1 2023 Earnings PreviewN/A
2023-04-02 18:12 ESTNewsVoyager: Preclinical Company With Major Big Pharma DealsN/A
2023-03-08 02:10 ESTNewsVoyager Therapeutics, Inc. (VYGR) Q4 2022 Earnings Call TranscriptN/A
2023-03-07 11:26 ESTNewsVoyager Therapeutics GAAP EPS of -$0.61 misses by $0.06N/A
2023-03-06 20:49 ESTNewsVoyager stock pops on getting $25M from Novartis under license dealN/A
2023-03-06 20:49 ESTNewsVoyager Therapeutics Q4 2022 Earnings PreviewN/A
2023-01-14 15:17 ESTNewsVoyager: Recent Neurocrine Deal Signals More UpsideN/A
2023-01-09 21:48 ESTNewsVoyager jumps 29% on licensing deal with NeurocrineN/A
2022-11-08 21:06 ESTNewsVoyager Therapeutics GAAP EPS of $0.45 beats by $0.79, revenue of $41.1M beats by $32.07MN/A
2022-11-08 21:05 ESTNewsVoyager Therapeutics, Inc. (VYGR) Q3 2022 Earnings Call TranscriptN/A
2022-11-08 02:33 ESTNewsVoyager Therapeutics Q3 2022 Earnings PreviewN/A
2022-10-04 22:59 ESTNewsVoyager stock rises as Pfizer opts to use AAV capsid for neurologic disease targetN/A
2022-09-07 09:01 ESTNewsVoyager Therapeutics hires new finance chiefN/A
2022-08-07 13:19 ESTNewsVoyager Therapeutics, Inc. (VYGR) CEO Dr. Al Sandrock on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-04 18:40 ESTNewsVoyager Therapeutics GAAP EPS of -$0.50 misses by $0.02N/A
2022-06-09 02:25 ESTNewsLooking Back In On Voyager TherapeuticsN/A
2022-05-05 12:49 ESTNewsVoyager Therapeutics GAAP EPS of -$0.56, revenue of $0.7M misses by $12.01MN/A
2022-04-22 03:14 ESTNewsVoyager Therapeutics plunges as board members departN/A
2022-03-26 15:30 ESTNewsVoyager Does A Reboot After First Generation FailuresN/A
2022-03-23 17:18 ESTNewsDr. Alfred W. Sandrock is the new CEO at Voyager therapeuticsN/A
2022-03-08 21:42 ESTNewsVoyager stock soars 15% on license deal with Novartis for AAV capsids for gene therapiesN/A
2022-03-08 21:42 ESTNewsVoyager Therapeutics GAAP EPS of $0.15 beats by $0.47, revenue of $28.07M beats by $13.52MN/A
2021-11-21 14:11 ESTNewsVoyager Therapeutics: Another Year, Another DealN/A
2021-11-03 01:45 ESTNewsVoyager Therapeutics EPS beats by $0.10, misses on revenueN/A
2021-10-20 17:49 ESTNewsVoyager Therapeutics falls despite gene therapy shows activity in preclinical studyN/A
2021-10-07 20:51 ESTNewsBaird upgrades Voyager Therapeutics to outperform on Pfizer deal; sees ~133% upsideN/A
2021-10-06 20:28 ESTNewsPfizer in pact with Voyager Therapeutics to develop gene therapiesN/A
2021-09-22 10:09 ESTNewsVoyager Therapeutics (VYGR) Investor Presentation - SlideshowN/A
2021-08-13 23:16 ESTNewsVoyager Therapeutics (VYGR) Presents At Canaccord Genuity Growth Conference Fireside ChatN/A
2021-08-09 17:17 ESTNewsVoyager launches new programs in Huntington's disease, ALS, and spinal muscular atropnyN/A
2021-07-22 08:38 ESTNewsVectoring In On Voyager TherapeuticsN/A
2021-04-26 09:15 ESTNewsVoyager shares rise as FDA lifts clinical hold on Huntington’s disease treatment INDN/A
2021-03-02 01:07 ESTAnalyst RatingThe Analyst Target Price has decreased from $10.35 to $10.25.Neutral
2021-03-01 12:35 ESTAnalyst RatingThe Analyst Target Price has decreased from $11.55 to $10.35.Neutral
2021-02-28 12:49 ESTFinancialsCompany financials have been released.Neutral
2021-02-28 00:50 ESTFinancialsCompany financials have been released.Neutral
2021-02-27 03:47 ESTNewsPremarket analyst action - healthcareN/A
2021-02-27 00:58 ESTFinancialsCompany financials have been released.Neutral
2021-02-26 09:20 ESTNewsVoyager Therapeutics EPS beats by $0.13, misses on revenueN/A
2021-02-26 09:19 ESTNewsVoyager Therapeutics, Inc. (VYGR) CEO Andre Turenne on Q4 2020 Results - Earnings Call TranscriptN/A
2021-02-26 04:54 ESTEarnings EstimateAn EPS average of -$2.86 is estimated for the 2022 year.Sell
2021-02-26 04:54 ESTEarnings EstimateAn EPS average of -$0.55 is estimated for the quarter ending on June 30, 2021.Sell
2021-02-04 12:59 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.09 to $11.55.Neutral
2021-02-04 03:50 ESTNewsVoyager sinks after BITG cut citing multiple clinical holdsN/A
2021-02-03 09:03 ESTNewsVoyager gets termination notice for Neurocrine Parkinson’s collaborationN/A
2021-01-19 04:47 ESTNewsVoyager Therapeutics: Complicated Story In Gene Therapy DevelopmentN/A
2020-12-24 17:20 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.75 to $14.09.Neutral
2020-12-23 17:23 ESTAnalyst RatingThe Analyst Target Price has decreased from $15.33 to $14.75.Neutral

About Voyager Therapeutics, Inc (VYGR):

Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia. The company has strategic collaboration agreements with the University of Massachusetts; and ClearPoint Neuro, Inc., as well as collaborations with Thermo Fisher Scientific and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

VYGR Quotes by TradingView

See Advanced Chart

General

  • Name Voyager Therapeutics, Inc
  • Symbol VYGR
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 177
  • Fiscal Year EndDecember
  • IPO Date2015-11-11
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.voyagertherapeutics.com
View More

Valuation

  • Trailing PE 5.57
  • Price/Sales (Trailing 12 Mt.) 1.26
  • Price/Book (Most Recent Quarter) 1.41
  • Enterprise Value Revenue 0.49
  • Enterprise Value EBITDA 2.7
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$2.84
  • Next Year EPS Estimate -$2.97
  • Next Quarter EPS Estimate -$0.51
  • Profit Margin 21%
  • Operating Margin 16%
  • Return on Assets 6%
  • Return on Equity 29%
  • Revenue 171.13 million
  • Earnings Per Share $0.98
  • Revenue Per Share $4.61
  • Gross Profit 62.38 million
  • Quarterly Earnings Growth -80%
View More

Highlights

  • Market Capitalization 205.59 million
  • EBITDA 31.2 million
  • PE Ratio 3.44
  • Analyst Target Price $10.25
  • Book Value Per Share $4.13
View More

Share Statistics

  • Shares Outstanding 37.65 million
  • Shares Float 22.58 million
  • % Held by Insiders 1407%
  • % Held by Institutions 74.93%
  • Shares Short 1.99 million
  • Shares Short Prior Month 1.89 million
  • Short Ratio 3.56
  • Short % of Float 8%
  • Short % of Shares Outstanding 5%
View More

Technicals

  • Beta 1.06
  • 52 Week High $14.62
  • 52 Week Low $5.18
  • 50 Day Moving Average 6.61
  • 200 Day Moving Average 8.94
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Voyager Therapeutics, Inc (VYGR) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Voyager Therapeutics, Inc (VYGR) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-25$N/A-$0.43-$0.5623.46%
2020-09-302020-11-09$N/A$2.27-$0.102416.33%
2020-06-302020-08-10$N/A-$0.23-$0.7368.61%
2020-03-312020-05-06$18.07 million-$0.66-$0.7916.61%
2019-12-312020-03-03$32.67 million-$0.34-$0.8157.93%
2019-09-302019-11-06$20.43 million-$0.41-$0.7343.84%
2019-06-302019-08-09$46.09 million$0.29-$0.81135.71%
2019-03-312019-05-07$5.2 million-$0.81-$0.78-4.03%
2018-12-312019-02-26$2.01 million-$0.70-$0.711.71%
2018-09-302018-11-07$2.09 million-$0.63-$0.7920.36%
2018-06-302018-08-07$2.58 million-$0.80-$0.66-20.61%
2018-03-312018-05-10$942000-$0.63-$0.62-1.61%
2017-12-312018-03-14$6.35 million-$0.40-$0.7344.87%
2017-09-302017-11-02$1.15 million-$0.89-$0.72-23.15%
2017-06-302017-08-08$1.18 million-$0.73-$0.61-20.66%
2017-03-312017-05-09$1.46 million-$0.65-$0.53-23.32%
2016-12-312017-03-15$2.36 million-$0.57-$0.46-24.37%
2016-09-302016-11-10$3.31 million-$0.35-$0.4114.22%
2016-06-302016-08-11$3.72 million-$0.37-$0.34-8.82%
2016-03-312016-05-12$4.83 million-$0.29-$0.3517.92%
2015-12-312016-03-17$4.94 million-$0.67-$0.62-8.06%
2015-09-302015-11-16$4.94 million-$5.25-$3.48-50.86%

Voyager Therapeutics, Inc (VYGR) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Voyager Therapeutics, Inc (VYGR) Chart:

VYGR chart by TradingView

Voyager Therapeutics, Inc (VYGR) News:

Below you will find a list of latest news for Voyager Therapeutics, Inc (VYGR) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Voyager Therapeutics, Inc (VYGR) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-05-172.50CALL0 00TRUE00
2024-05-1754.75CALL0 40471.13TRUE00
2024-05-177.51.25CALL18 125114.25TRUE0.651.08
2024-05-17100.25CALL61 414110.61FALSE0.10.67
2024-05-1712.50.06CALL0 500FALSE00
2024-05-17150.27CALL0 260FALSE00
2024-05-1717.50.2CALL0 10FALSE00
2024-05-17200CALL0 00FALSE00
2024-05-172.50PUT0 00FALSE00
2024-05-1750.05PUT0 200FALSE00
2024-05-177.50.25PUT9 22391.77FALSE0.250
2024-05-17102.41PUT0 8196.52TRUE00
2024-05-1712.52.55PUT0 10308.57TRUE00
2024-05-17150PUT0 0358.31TRUE00
2024-05-1717.50PUT0 0419.65TRUE00
2024-05-17200PUT0 0448.26TRUE00
2024-06-212.50CALL0 0873.55TRUE00
2024-06-2152.51CALL0 1104.94TRUE00
2024-06-217.50.95CALL0 235.72TRUE00
2024-06-21100.45CALL10 2978.44FALSE0.450
2024-06-2112.50.07CALL0 190.76FALSE00
2024-06-21150CALL0 00FALSE00
2024-06-212.50PUT0 00FALSE00
2024-06-2150PUT0 00FALSE00
2024-06-217.50.5PUT3 2675.83FALSE0.50
2024-06-21100PUT0 0137.13TRUE00
2024-06-2112.50PUT0 086.71TRUE00
2024-06-21150PUT0 0187.25TRUE00
2024-07-192.50CALL0 0275.43TRUE00
2024-07-1953.2CALL34 8979.92TRUE3.20
2024-07-197.51.6CALL1 70873.3TRUE1.60
2024-07-19100.45CALL0 26272.59FALSE00
2024-07-1912.50.25CALL1 7477.29FALSE0.250
2024-07-19150.05CALL0 1290FALSE00
2024-07-1917.50.5CALL0 70FALSE00
2024-07-19200.2CALL0 310FALSE00
2024-07-192.50PUT0 00FALSE00
2024-07-1950.27PUT0 1730FALSE00
2024-07-197.50.95PUT0 24678.31FALSE00
2024-07-19102.5PUT0 9469.57TRUE00
2024-07-1912.54.2PUT0 783.08TRUE00
2024-07-19156.1PUT0 0163.41TRUE00
2024-07-1917.50PUT0 0191.35TRUE00
2024-07-19200PUT0 0208.65TRUE00
2024-10-182.57CALL0 1214.9TRUE00
2024-10-1853.2CALL0 360.49TRUE00
2024-10-187.51.8CALL1 24357.08TRUE0.050.03
2024-10-18101.1CALL30 21370.2FALSE1.10
2024-10-1812.50.55CALL1 7168.61FALSE0.550
2024-10-18150.3CALL0 4077.64FALSE00
2024-10-1817.50CALL0 094.51FALSE00
2024-10-182.50PUT0 00FALSE00
2024-10-1850.2PUT0 1375.95FALSE00
2024-10-187.51.47PUT0 4565.17FALSE00
2024-10-18103PUT0 1974.38TRUE00
2024-10-1812.54.2PUT0 385.54TRUE00
2024-10-18156.78PUT0 670.76TRUE00
2024-10-1817.59.2PUT0 21121.53TRUE00

Latest VYGR Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST67$4.985
Jun 13, 2022 7:59 PM EST3$4.985
Jun 13, 2022 7:59 PM EST18$4.99
Jun 13, 2022 7:59 PM EST17$4.99
Jun 13, 2022 7:59 PM EST100$4.985

Voyager Therapeutics, Inc (VYGR) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1640266/000110465920071432/0001104659-20-071432-index.htm
2019-11-19UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1640266/000000000019015636/0000000000-19-015636-index.htm
2019-02-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1640266/000021545719006579/0000215457-19-006579-index.htm
2018-08-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1640266/000031506618002168/0000315066-18-002168-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1640266/000031506619001427/0000315066-19-001427-index.htm
2020-02-06SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1640266/000083423720006893/0000834237-20-006893-index.htm
2018-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000089924318017586/0000899243-18-017586-index.htm
2018-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000089924318017587/0000899243-18-017587-index.htm
2018-09-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000089924318024774/0000899243-18-024774-index.htm
2018-09-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000089924318024777/0000899243-18-024777-index.htm
2018-09-21SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1640266/000091957418006282/0000919574-18-006282-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1640266/000091957419001760/0000919574-19-001760-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1640266/000091957420001444/0000919574-20-001444-index.htm
2020-03-05SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1640266/000091957420002138/0000919574-20-002138-index.htm
2019-11-06S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1640266/000104746919006100/0001047469-19-006100-index.htm
2019-12-03424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1640266/000104746919006602/0001047469-19-006602-index.htm
2018-03-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465918019018/0001104659-18-019018-index.htm
2018-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465918020100/0001104659-18-020100-index.htm
2018-04-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465918023708/0001104659-18-023708-index.htm
2018-05-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1640266/000110465918036438/0001104659-18-036438-index.htm
2018-06-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1640266/000110465918038314/0001104659-18-038314-index.htm
2018-06-153Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465918040463/0001104659-18-040463-index.htm
2018-06-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1640266/000110465918040465/0001104659-18-040465-index.htm
2018-06-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465918040887/0001104659-18-040887-index.htm
2018-06-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465918040889/0001104659-18-040889-index.htm
2018-06-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465918040890/0001104659-18-040890-index.htm
2018-06-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465918040891/0001104659-18-040891-index.htm
2018-06-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465918040892/0001104659-18-040892-index.htm
2018-06-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465918040894/0001104659-18-040894-index.htm
2018-06-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465918040895/0001104659-18-040895-index.htm
2018-06-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1640266/000110465918042962/0001104659-18-042962-index.htm
2018-07-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465918045812/0001104659-18-045812-index.htm
2018-07-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465918045813/0001104659-18-045813-index.htm
2018-08-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465918053030/0001104659-18-053030-index.htm
2018-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465918056499/0001104659-18-056499-index.htm
2018-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465918056500/0001104659-18-056500-index.htm
2018-11-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465918067413/0001104659-18-067413-index.htm
2019-01-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465919002346/0001104659-19-002346-index.htm
2019-01-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465919002347/0001104659-19-002347-index.htm
2019-01-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465919002348/0001104659-19-002348-index.htm
2019-01-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465919002349/0001104659-19-002349-index.htm
2019-01-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1640266/000110465919003840/0001104659-19-003840-index.htm
2019-02-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1640266/000110465919009995/0001104659-19-009995-index.htm
2019-02-26S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1640266/000110465919010753/0001104659-19-010753-index.htm
2019-03-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1640266/000110465919014279/0001104659-19-014279-index.htm
2019-04-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465919019771/0001104659-19-019771-index.htm
2019-04-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465919019772/0001104659-19-019772-index.htm
2019-05-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1640266/000110465919030857/0001104659-19-030857-index.htm
2019-05-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465919031176/0001104659-19-031176-index.htm
2019-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465919031178/0001104659-19-031178-index.htm
2019-06-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1640266/000110465919035658/0001104659-19-035658-index.htm
2019-06-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1640266/000110465919035796/0001104659-19-035796-index.htm
2019-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465919035995/0001104659-19-035995-index.htm
2019-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465919035996/0001104659-19-035996-index.htm
2019-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465919035997/0001104659-19-035997-index.htm
2019-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465919035998/0001104659-19-035998-index.htm
2019-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465919036000/0001104659-19-036000-index.htm
2019-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465919036003/0001104659-19-036003-index.htm
2019-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465919036004/0001104659-19-036004-index.htm
2019-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465919036005/0001104659-19-036005-index.htm
2019-11-22CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1640266/000110465919066634/0001104659-19-066634-index.htm
2019-11-27CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1640266/000110465919068177/0001104659-19-068177-index.htm
2020-01-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465920008187/0001104659-20-008187-index.htm
2020-01-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465920008188/0001104659-20-008188-index.htm
2020-01-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465920008190/0001104659-20-008190-index.htm
2020-02-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1640266/000110465920016411/0001104659-20-016411-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465920019448/0001104659-20-019448-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465920019453/0001104659-20-019453-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465920019455/0001104659-20-019455-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465920019457/0001104659-20-019457-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1640266/000110465920021672/0001104659-20-021672-index.htm
2020-02-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1640266/000110465920021963/0001104659-20-021963-index.htm
2020-03-03S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1640266/000110465920028678/0001104659-20-028678-index.htm
2020-03-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1640266/000110465920035610/0001104659-20-035610-index.htm
2020-04-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465920044247/0001104659-20-044247-index.htm
2020-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465920065492/0001104659-20-065492-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465920070318/0001104659-20-070318-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465920070323/0001104659-20-070323-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465920070326/0001104659-20-070326-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465920070327/0001104659-20-070327-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465920070328/0001104659-20-070328-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465920070329/0001104659-20-070329-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465920070330/0001104659-20-070330-index.htm
2020-06-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1640266/000110465920071432/0001104659-20-071432-index.htm
2020-08-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1640266/000110465920089624/0001104659-20-089624-index.htm
2020-09-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1640266/000110465920105222/0001104659-20-105222-index.htm
2020-09-163Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465920105664/0001104659-20-105664-index.htm
2020-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000110465920105669/0001104659-20-105669-index.htm
2019-04-01SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1640266/000114420419017415/0001144204-19-017415-index.htm
2019-02-11SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1640266/000119312519033129/0001193125-19-033129-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1640266/000119312519037847/0001193125-19-037847-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1640266/000119312519037913/0001193125-19-037913-index.htm
2019-02-15SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1640266/000119312519042298/0001193125-19-042298-index.htm
2020-02-11SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1640266/000119312520030574/0001193125-20-030574-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1640266/000119312520037830/0001193125-20-037830-index.htm
2019-03-143Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000120919119019450/0001209191-19-019450-index.htm
2019-03-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1640266/000120919119019459/0001209191-19-019459-index.htm
2018-04-27DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1640266/000155837018003377/0001558370-18-003377-index.htm
2018-05-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1640266/000155837018004570/0001558370-18-004570-index.htm
2018-05-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1640266/000155837018004575/0001558370-18-004575-index.htm
2018-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1640266/000155837018006605/0001558370-18-006605-index.htm
2018-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1640266/000155837018006628/0001558370-18-006628-index.htm
2018-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1640266/000155837018008805/0001558370-18-008805-index.htm
2018-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1640266/000155837018008821/0001558370-18-008821-index.htm
2019-02-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1640266/000155837019001085/0001558370-19-001085-index.htm
2019-02-2610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1640266/000155837019001105/0001558370-19-001105-index.htm
2019-04-23DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1640266/000155837019003181/0001558370-19-003181-index.htm
2019-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1640266/000155837019004159/0001558370-19-004159-index.htm
2019-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1640266/000155837019004165/0001558370-19-004165-index.htm
2019-08-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1640266/000155837019007805/0001558370-19-007805-index.htm
2019-08-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1640266/000155837019007823/0001558370-19-007823-index.htm
2019-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1640266/000155837019010064/0001558370-19-010064-index.htm
2019-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1640266/000155837019010066/0001558370-19-010066-index.htm
2020-03-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1640266/000155837020001965/0001558370-20-001965-index.htm
2020-03-0310-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1640266/000155837020001974/0001558370-20-001974-index.htm
2020-04-22DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1640266/000155837020004158/0001558370-20-004158-index.htm
2020-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1640266/000155837020005285/0001558370-20-005285-index.htm
2020-05-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1640266/000155837020005300/0001558370-20-005300-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1640266/000155837020010039/0001558370-20-010039-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1640266/000155837020010047/0001558370-20-010047-index.htm
2019-03-14SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1640266/000156459019007831/0001564590-19-007831-index.htm
2019-12-02EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1640266/999999999519002724/9999999995-19-002724-index.htm
2018-04-05CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1640266/999999999718004233/9999999997-18-004233-index.htm
2019-03-19CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1640266/999999999719001305/9999999997-19-001305-index.htm

Voyager Therapeutics, Inc (VYGR) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Voyager Therapeutics, Inc (VYGR). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1407%
Institutional Ownership: 7493%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-04-10Bernard RavinaChief Medical OfficerSell2,451.0018.3845,049.380.00https://www.sec.gov/Archives/edgar/data/1640266/000110465918023708/0001104659-18-023708-index.htm
2018-03-16Jane HendersonCFO & SVP, Corp. Dev.Sell15,416.0022.15341,464.400.00https://www.sec.gov/Archives/edgar/data/1640266/000110465918019018/0001104659-18-019018-index.htm
2018-03-19Jane HendersonCFO & SVP, Corp. Dev.Sell1,900.0021.7641,344.000.00https://www.sec.gov/Archives/edgar/data/1640266/000110465918019018/0001104659-18-019018-index.htm
2018-03-22Jane HendersonSr. V.P. & CFO, Corp. Dev.Sell19,900.0021.07419,293.000.00https://www.sec.gov/Archives/edgar/data/1640266/000110465918020100/0001104659-18-020100-index.htm
2018-03-23Jane HendersonSr. V.P. & CFO, Corp. Dev.Sell11,200.0020.52229,824.000.00https://www.sec.gov/Archives/edgar/data/1640266/000110465918020100/0001104659-18-020100-index.htm
2018-03-23Jane HendersonSr. V.P. & CFO, Corp. Dev.Buy11,200.0011.97134,064.0011,200.00https://www.sec.gov/Archives/edgar/data/1640266/000110465918020100/0001104659-18-020100-index.htm
2018-03-16Jane HendersonCFO & SVP, Corp. Dev.Buy15,416.0011.97184,529.5215,416.00https://www.sec.gov/Archives/edgar/data/1640266/000110465918019018/0001104659-18-019018-index.htm
2019-01-11Dinah Ph.D. SahChief Scientific OfficerBuy25,000.00163,688.00https://www.sec.gov/Archives/edgar/data/1640266/000110465919002348/0001104659-19-002348-index.htm
2020-02-10Andre TurennePresident & CEOBuy81,250.00166,795.00https://www.sec.gov/Archives/edgar/data/1640266/000110465920019448/0001104659-20-019448-index.htm
2018-03-19Jane HendersonCFO & SVP, Corp. Dev.Buy1,900.0011.9722,743.001,900.00https://www.sec.gov/Archives/edgar/data/1640266/000110465918019018/0001104659-18-019018-index.htm
2018-03-22Jane HendersonSr. V.P. & CFO, Corp. Dev.Buy19,900.0011.97238,203.0019,900.00https://www.sec.gov/Archives/edgar/data/1640266/000110465918020100/0001104659-18-020100-index.htm
2020-01-21Allison DorvalChief Financial OfficerSell3,128.0013.3641,790.0824,522.00https://www.sec.gov/Archives/edgar/data/1640266/000110465920008190/0001104659-20-008190-index.htm
2019-01-11Allison DorvalChief Financial OfficerBuy25,000.0026,106.00https://www.sec.gov/Archives/edgar/data/1640266/000110465919002346/0001104659-19-002346-index.htm
2020-01-21Matthew P. OttmerChief Operating OfficerSell3,724.0013.3649,752.6426,276.00https://www.sec.gov/Archives/edgar/data/1640266/000110465920008188/0001104659-20-008188-index.htm
2019-04-01Robert W. HessleinSenior VP & General CounselBuy28,125.0028,125.00https://www.sec.gov/Archives/edgar/data/1640266/000110465919019772/0001104659-19-019772-index.htm
2019-01-11Matthew P. OttmerChief Operating OfficerBuy30,000.0030,000.00https://www.sec.gov/Archives/edgar/data/1640266/000110465919002347/0001104659-19-002347-index.htm
2019-05-20Omar KhwajaOfficerBuy30,000.0030,000.00https://www.sec.gov/Archives/edgar/data/1640266/000110465919031178/0001104659-19-031178-index.htm
2019-03-12NEUROCRINE BIOSCIENCES INC10% Share HolderBuy4,179,728.0011.9649,999,996.204,179,728.00https://www.sec.gov/Archives/edgar/data/1640266/000120919119019459/0001209191-19-019459-index.htm
2018-09-12GLENN PIERCEDirectorBuy5,000.0018.4492,200.005,000.00https://www.sec.gov/Archives/edgar/data/1640266/000110465918056499/0001104659-18-056499-index.htm
2020-02-10Allison DorvalChief Financial OfficerBuy27,500.0052,022.00https://www.sec.gov/Archives/edgar/data/1640266/000110465920019457/0001104659-20-019457-index.htm
2020-04-03Robert W. HessleinSenior VP & General CounselSell3,091.008.5126,304.4152,534.00https://www.sec.gov/Archives/edgar/data/1640266/000110465920044247/0001104659-20-044247-index.htm
2020-02-10Robert W. HessleinSenior VP & General CounselBuy27,500.0055,625.00https://www.sec.gov/Archives/edgar/data/1640266/000110465920019455/0001104659-20-019455-index.htm
2020-05-21Omar KhwajaOfficerSell3,500.0012.9645,360.0056,500.00https://www.sec.gov/Archives/edgar/data/1640266/000110465920065492/0001104659-20-065492-index.htm
2020-02-10Omar KhwajaOfficerBuy30,000.0060,000.00https://www.sec.gov/Archives/edgar/data/1640266/000110465920019453/0001104659-20-019453-index.htm
2018-08-17JAMES A GERAGHTYDirectorBuy3,000.0018.3154,930.0073,588.00https://www.sec.gov/Archives/edgar/data/1640266/000110465918053030/0001104659-18-053030-index.htm
2018-09-10JAMES A GERAGHTYDirectorBuy3,000.0019.3958,170.0076,588.00https://www.sec.gov/Archives/edgar/data/1640266/000110465918056500/0001104659-18-056500-index.htm
2020-01-21Andre TurennePresident & CEOSell10,705.0013.36143,018.8085,545.00https://www.sec.gov/Archives/edgar/data/1640266/000110465920008187/0001104659-20-008187-index.htm
2019-01-11Andre TurennePresident & CEOBuy96,250.0096,250.00https://www.sec.gov/Archives/edgar/data/1640266/000110465919002349/0001104659-19-002349-index.htm